SIR-0365

N/A

Report date: 2022/01/10 15:31:35
NME

Base Information

Drug NameSIR-0365
Drug Alias NameSIR-0365
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionReceptor-interacting serine/threonine-protein kinase 1 inhibitors
TargetsReceptor-interacting serine/threonine-protein kinase 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSironax (Beijing) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSironax (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A